In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
When innovation outpaces access: Closing the gap in chronic lymphocytic leukemia care
New targeted therapies have extended survival, improved quality of life, and enabled more personalized treatment decisions based on genetic risk factors, age,...